$251 Million is the total value of Virtus ETF Advisers LLC's 436 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2022 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| REGENERON PHARMACEUTICALS | 31 | Q3 2023 | 1.8% |
| INCYTE CORP | 31 | Q3 2023 | 2.1% |
| ENANTA PHARMACEUTICALS INC | 31 | Q3 2023 | 2.2% |
| EXELIXIS INC | 31 | Q3 2023 | 1.8% |
| VANDA PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| IRONWOOD PHARMACEUTICALS INC | 31 | Q3 2023 | 2.0% |
| LIGAND PHARMACEUTICALS INC | 31 | Q3 2023 | 1.5% |
| GILEAD SCIENCES INC | 31 | Q3 2023 | 1.6% |
| HALOZYME THERAPEUTICS INC | 31 | Q3 2023 | 1.7% |
View Virtus ETF Advisers LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-15 |
| 13F-HR | 2023-11-07 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Virtus ETF Advisers LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.